Clinical Trials

Vistar Eye Centers participate in clinical studies throughout the year. Below you will find a summary of our current studies. Join us in our vision for cutting-edge eye health research.

For more information or to discover if you are a candidate for participation, call Vistar Eye Center's Clinical Studies Department at 540-855-3547.

Investigational Study: Eye Drop Following Cataract Surgery

Enrollment Begins September 2014

Dr. John Wood (primarily investigator)

Vistar Eye Center’s Dr. John Wood is conducting a clinical research study to collect data evaluating the safety and effectiveness of an investigational study eye drop. This eye drop may not be approved by the FDA.

The new eye drop is being tested for its effectiveness in the reduction of inflammation and pain following cataract surgery.

Dr. John Wood, a board-certified ophthalmologist with a specialty in cataract surgery, will conduct the clinical research. Participating patients will receive drops in one eye after cataract surgery.

The patient will use the drop for approximately 2 weeks. During this time period, the patient will visit Vistar Eye Center about 7 times for testing. The drops will be supplied free of change and patients will be paid for participation. The patient must need cataract surgery in one or both eyes, and cannot take any NSAIDS (oral anti inflammatory medication) for the duration of the study.

If you feel you could be a candidate for this study, please contact us as soon as possible.

High-Powered Toric IOL

Dr. John Wood and Dr. David Kinsler (primary investigators)

Drs. Wood and Kinsler are participating in a post-market clinical study of a High Powered Toric IOL (Intraocular Lens) that has been approved by the FDA and is currently being used in surgeries.

The purpose of the study is to compare the efficacy of this new lens with the current standard lens. Specifically, the study will compare the amount of post-operative visual distortion experienced by patients who had >2.57 diopters of astigmatism and cataracts in both eyes, and want to be implanted with the standard SN60WF.

The standard SN60WF lens is covered by insurance. Patients choosing the Toric Lens are responsible for the added cost of this premium lens, and would not be able to be enrolled in this study.

We are currently only enrolling patients who want the standard implant.

GLAUKOS - Suprachoroidal Stent in Conjunction with Cataract Surgery

Dr. Frank Cotter (primary investigator)

Dr. Frank Cotter, the Primary Investigator for this clinical research, will collect data over a two-year period, evaluating the outcome on a device used when doing cataract surgery on a person with Open Angle Glaucoma. This device is being evaluated on the effect of reducing intraocular pressure after a stent is implanted in conjunction with cataract surgery.

Patients will be followed for two years postoperatively to document the outcome. Dr Cotter is a board-certified ophthalmologist who specializes in the treatment of Glaucoma.

If you feel you could be a candidate for this study, please contact us.

ALLERGAN- Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension

Dr. Cotter is also Primary Investigator in a clinical research trial that will be evaluating the Safety & Efficacy of the use of Bimatoprost SR (a sustained-release Intracameral Drug delivery system) in one eye. The administration of the drug will be done in our office every 16 weeks. Glaucoma drops will still be used on a daily basis. This study will last approximately two years.